GTBP GT Biopharma, Inc.
USHealthcareAs of 2026-07-08 16:00
Why GTBP matters now
GT Biopharma, Inc. (GTBP) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.47 with +1.65% on the session and $5.0M in market capitalization; recent performance reads 1-month +19.53% and YTD -34.54%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.8M, and EPS of $-0.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -241.4%.
The latest indexable market news headline is "Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.05
P/S
0.00
EV/EBITDA
0.07
DCF Value
$1.11
FCF Yield
-241.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-901.3%
ROA
-477.5%
ROIC
-205.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.8M | $-0.11 |
| Q4 2025 | $0.00 | $-23.0M | $-4.97 |
| FY 2025 | $0.00 | $-28.4M | $-6.25 |
| Q3 2025 | $0.00 | $8.3M | $-0.83 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.86
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.